{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T03:24:17Z","timestamp":1786937057838,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04941-6","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:28:00Z","timestamp":1786933680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy"],"prefix":"10.1007","volume":"96","author":[{"given":"Guangmao","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingcan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxia","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-404X","authenticated-orcid":false,"given":"Mark L.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1147-9444","authenticated-orcid":false,"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"9","key":"4941_CR1","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1158\/0008-5472.CAN-20-2978","volume":"81","author":"T Khan","year":"2021","unstructured":"Khan T, Kryza T, Lyons NJ, He Y, Hooper JD (2021) The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention. Cancer Res 81(9):2259\u20132269. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-2978","journal-title":"Cancer Res"},{"key":"4941_CR2","doi-asserted-by":"publisher","first-page":"120600","DOI":"10.1016\/j.lfs.2022.120600","volume":"301","author":"X Qi","year":"2022","unstructured":"Qi X, Gao J, Li Z, Zhang G, Li J, Fu Y, Cai M, Wang H, Tong T (2022) CDCP1: A promising diagnostic biomarker and therapeutic target for human cancer. Life Sci 301:120600. https:\/\/doi.org\/10.1016\/j.lfs.2022.120600","journal-title":"Life Sci"},{"issue":"12","key":"4941_CR3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.onc.1206220","volume":"22","author":"JD Hooper","year":"2003","unstructured":"Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135\/CDCP1, a 135\u00a0kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22(12):1783\u20131794. https:\/\/doi.org\/10.1038\/sj.onc.1206220","journal-title":"Oncogene"},{"issue":"3","key":"4941_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1634\/stemcells.22-3-334","volume":"22","author":"HJ Buhring","year":"2004","unstructured":"Buhring HJ, Kuci S, Conze T, Rathke G, Bartolovic K, Grunebach F, Scherl-Mostageer M, Brummendorf TH, Schweifer N, Lammers R (2004) CDCP1 identifies a broad spectrum of normal and malignant stem\/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells 22(3):334\u2013343. https:\/\/doi.org\/10.1634\/stemcells.22-3-334","journal-title":"Stem Cells"},{"key":"4941_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/1471-2407-14-754","volume":"14","author":"DJ Orchard-Webb","year":"2014","unstructured":"Orchard-Webb DJ, Lee TC, Cook GP, Blair GE (2014) CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. BMC Cancer 14:754. https:\/\/doi.org\/10.1186\/1471-2407-14-754","journal-title":"BMC Cancer"},{"issue":"11","key":"4941_CR6","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1111\/j.1349-7006.2011.02052.x","volume":"102","author":"T Uekita","year":"2011","unstructured":"Uekita T, Sakai R (2011) Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis. Cancer Sci 102(11):1943\u20131948. https:\/\/doi.org\/10.1111\/j.1349-7006.2011.02052.x","journal-title":"Cancer Sci"},{"issue":"33","key":"4941_CR7","doi-asserted-by":"publisher","first-page":"E6912","DOI":"10.1073\/pnas.1704008114","volume":"114","author":"G Enyindah-Asonye","year":"2017","unstructured":"Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F (2017) CD318 is a ligand for CD6. Proc Natl Acad Sci USA 114(33):E6912\u2013E6921. https:\/\/doi.org\/10.1073\/pnas.1704008114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"4941_CR8","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.7150\/thno.78171","volume":"12","author":"T Khan","year":"2022","unstructured":"Khan T, Lyons NJ, Gough M, Kwah KKX, Cuda TJ, Snell CE, Tse BW, Sokolowski KA, Pearce LA, Adams TE, Rose SE, Puttick S, Pajic M, Adams MN, He Y, Hooper JD, Kryza T (2022) CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics 12(16):6915\u20136930. https:\/\/doi.org\/10.7150\/thno.78171","journal-title":"Theranostics"},{"issue":"14","key":"4941_CR9","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1158\/1078-0432.CCR-20-0268","volume":"26","author":"A Moroz","year":"2020","unstructured":"Moroz A, Wang YH, Sharib JM, Wei J, Zhao N, Huang Y, Chen Z, Martinko AJ, Zhuo J, Lim SA, Zhang LH, Seo Y, Carlin S, Leung KK, Collisson EA, Kirkwood KS, Wells JA, Evans MJ (2020) Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer. Clin Cancer Res 26(14):3608\u20133615. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0268","journal-title":"Clin Cancer Res"},{"issue":"13","key":"4941_CR10","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1245\/s10434-015-4505-4","volume":"22","author":"CT Chou","year":"2015","unstructured":"Chou CT, Li YJ, Chang CC, Yang CN, Li PS, Jeng YM, Chen ST, Kuo ML, Lin IC, Lin BR (2015) Prognostic Significance of CDCP1 Expression in Colorectal Cancer and Effect of Its Inhibition on Invasion and Migration. Ann Surg Oncol 22(13):4335\u20134343. https:\/\/doi.org\/10.1245\/s10434-015-4505-4","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"4941_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41598-022-26579-z","volume":"13","author":"M Saponaro","year":"2023","unstructured":"Saponaro M, Flottmann S, Eckstein M, Hommerding O, Klumper N, Corvino D, Hosni S, Schmidt A, Monig N, Schmidt D, Ellinger J, Toma M, Kristiansen G, Bald T, Alimonti A, Ritter M, Holzel M, Alajati A (2023) CDCP1 expression is frequently increased in aggressive urothelial carcinoma and promotes urothelial tumor progression. Sci Rep 13(1):73. https:\/\/doi.org\/10.1038\/s41598-022-26579-z","journal-title":"Sci Rep"},{"issue":"5","key":"4941_CR12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1172\/JCI131133","volume":"130","author":"A Alajati","year":"2020","unstructured":"Alajati A, D\u2019Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D\u2019Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Camplese L, Hirabayashi S, Canato E, Pasut G, Montopoli M, Ruschoff JH, Wild P, Moch H, De Bono J, Alimonti A (2020) CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. J Clin Invest 130(5):2435\u20132450. https:\/\/doi.org\/10.1172\/JCI131133","journal-title":"J Clin Invest"},{"issue":"12","key":"4941_CR13","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1158\/0008-5472.CAN-10-0220","volume":"70","author":"Y Miyazawa","year":"2010","unstructured":"Miyazawa Y, Uekita T, Hiraoka N, Fujii S, Kosuge T, Kanai Y, Nojima Y, Sakai R (2010) CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 70(12):5136\u20135146. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-0220","journal-title":"Cancer Res"},{"issue":"1","key":"4941_CR14","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41467-021-21774-4","volume":"12","author":"D Schafer","year":"2021","unstructured":"Schafer D, Tomiuk S, Kuster LN, Rawashdeh WA, Henze J, Tischler-Hohle G, Agorku DJ, Brauner J, Linnartz C, Lock D, Kaiser A, Herbel C, Eckardt D, Lamorte M, Lenhard D, Schuler J, Strobel P, Missbach-Guentner J, Pinkert-Leetsch D, Alves F, Bosio A, Hardt O (2021) Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 12(1):1453. https:\/\/doi.org\/10.1038\/s41467-021-21774-4","journal-title":"Nat Commun"},{"issue":"10","key":"4941_CR15","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/1541-7786.MCR-13-0587","volume":"12","author":"T Uekita","year":"2014","unstructured":"Uekita T, Fujii S, Miyazawa Y, Iwakawa R, Narisawa-Saito M, Nakashima K, Tsuta K, Tsuda H, Kiyono T, Yokota J, Sakai R (2014) Oncogenic Ras\/ERK signaling activates CDCP1 to promote tumor invasion and metastasis. Mol Cancer Res 12(10):1449\u20131459. https:\/\/doi.org\/10.1158\/1541-7786.MCR-13-0587","journal-title":"Mol Cancer Res"},{"key":"4941_CR16","doi-asserted-by":"publisher","unstructured":"Lim SA, Zhou J, Martinko AJ, Wang YH, Filippova EV, Steri V, Wang D, Remesh SG, Liu J, Hann B, Kossiakoff AA, Evans MJ, Leung KK, Wells JA (2022) Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest 132(4). https:\/\/doi.org\/10.1172\/JCI154604","DOI":"10.1172\/JCI154604"},{"issue":"1","key":"4941_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.18632\/oncoscience.286","volume":"3","author":"Y He","year":"2016","unstructured":"He Y, Harrington BS, Hooper JD (2016) New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways. Oncoscience 3(1):5\u20138. https:\/\/doi.org\/10.18632\/oncoscience.286","journal-title":"Oncoscience"},{"issue":"4","key":"4941_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.celrep.2015.03.044","volume":"11","author":"A Alajati","year":"2015","unstructured":"Alajati A, Guccini I, Pinton S, Garcia-Escudero R, Bernasocchi T, Sarti M, Montani E, Rinaldi A, Montemurro F, Catapano C, Bertoni F, Alimonti A (2015) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. Cell Rep 11(4):564\u2013576. https:\/\/doi.org\/10.1016\/j.celrep.2015.03.044","journal-title":"Cell Rep"},{"issue":"3","key":"4941_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00277-020-03907-9","volume":"99","author":"JS Heitmann","year":"2020","unstructured":"Heitmann JS, Hagelstein I, Hinterleitner C, Roerden M, Jung G, Salih HR, Marklin M, Kauer J (2020) Identification of CD318 (CDCP1) as novel prognostic marker in AML. Ann Hematol 99(3):477\u2013486. https:\/\/doi.org\/10.1007\/s00277-020-03907-9","journal-title":"Ann Hematol"},{"issue":"34","key":"4941_CR20","doi-asserted-by":"publisher","first-page":"26162","DOI":"10.1074\/jbc.M109.096453","volume":"285","author":"Y He","year":"2010","unstructured":"He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, Quigley JP, Leduc R, Kirchhofer D, Hooper JD (2010) Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J Biol Chem 285(34):26162\u201326173. https:\/\/doi.org\/10.1074\/jbc.M109.096453","journal-title":"J Biol Chem"},{"key":"4941_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jpba.2017.02.047","volume":"139","author":"Y Chen","year":"2017","unstructured":"Chen Y, Harrington BS, Lau KCN, Burke LJ, He Y, Iconomou M, Palmer JS, Meade B, Lumley JW, Hooper JD (2017) Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens. J Pharm Biomed Anal 139:65\u201372. https:\/\/doi.org\/10.1016\/j.jpba.2017.02.047","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"4941_CR22","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.7150\/thno.43589","volume":"10","author":"T Kryza","year":"2020","unstructured":"Kryza T, Khan T, Puttick S, Li C, Sokolowski KA, Tse BW, Cuda T, Lyons N, Gough M, Yin J, Parkin A, Deryugina EI, Quigley JP, Law RHP, Whisstock JC, Riddell AD, Barbour AP, Wyld DK, Thomas PA, Rose S, Snell CE, Pajic M, He Y, Hooper JD (2020) Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma. Theranostics 10(9):4116\u20134133. https:\/\/doi.org\/10.7150\/thno.43589","journal-title":"Theranostics"},{"issue":"14","key":"4941_CR23","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1158\/1078-0432.CCR-21-3858","volume":"28","author":"N Zhao","year":"2022","unstructured":"Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ (2022) CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res 28(14):3066\u20133075. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3858","journal-title":"Clin Cancer Res"},{"key":"4941_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","volume":"40","author":"D Neri","year":"2016","unstructured":"Neri D, Sondel PM (2016) Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40:96\u2013102. https:\/\/doi.org\/10.1016\/j.coi.2016.03.006","journal-title":"Curr Opin Immunol"},{"issue":"41","key":"4941_CR25","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano RFV, Hunger A, Mendonca SA, Barbuto JAM, Strauss BE (2017) Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 8(41):71249\u201371284. https:\/\/doi.org\/10.18632\/oncotarget.19531","journal-title":"Oncotarget"},{"issue":"1","key":"4941_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-022-00415-y","volume":"10","author":"F Xiong","year":"2022","unstructured":"Xiong F, Wang Q, Wu GH, Liu WZ, Wang B, Chen YJ (2022) Direct and indirect effects of IFN-alpha2b in malignancy treatment: not only an archer but also an arrow. Biomark Res 10(1):69. https:\/\/doi.org\/10.1186\/s40364-022-00415-y","journal-title":"Biomark Res"},{"key":"4941_CR27","doi-asserted-by":"publisher","unstructured":"Asmana Ningrum R (2014) Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo) 2014:970315. https:\/\/doi.org\/10.1155\/2014\/970315","DOI":"10.1155\/2014\/970315"},{"key":"4941_CR28","doi-asserted-by":"publisher","first-page":"117426","DOI":"10.1016\/j.biopha.2024.117426","volume":"179","author":"J Lim","year":"2024","unstructured":"Lim J, Lee HK (2024) Engineering interferons for cancer immunotherapy. Biomed Pharmacother 179:117426. https:\/\/doi.org\/10.1016\/j.biopha.2024.117426","journal-title":"Biomed Pharmacother"},{"issue":"18","key":"4941_CR29","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood-2009-06-228890","volume":"114","author":"EA Rossi","year":"2009","unstructured":"Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (2009) CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114(18):3864\u20133871. https:\/\/doi.org\/10.1182\/blood-2009-06-228890","journal-title":"Blood"},{"issue":"9","key":"4941_CR30","doi-asserted-by":"publisher","first-page":"e0162472","DOI":"10.1371\/journal.pone.0162472","volume":"11","author":"SL Pogue","year":"2016","unstructured":"Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock M, Sanchez E, Chen H, Berenson J, Doyle A, Nock S, Wilson DS (2016) Targeting Attenuated Interferon-alpha to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. PLoS ONE 11(9):e0162472. https:\/\/doi.org\/10.1371\/journal.pone.0162472","journal-title":"PLoS ONE"},{"issue":"7","key":"4941_CR31","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2011-03-343145","volume":"118","author":"EA Rossi","year":"2011","unstructured":"Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH (2011) Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood 118(7):1877\u20131884. https:\/\/doi.org\/10.1182\/blood-2011-03-343145","journal-title":"Blood"},{"issue":"51","key":"4941_CR32","doi-asserted-by":"publisher","first-page":"40425","DOI":"10.1074\/jbc.M006854200","volume":"275","author":"J Piehler","year":"2000","unstructured":"Piehler J, Roisman LC, Schreiber G (2000) New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem 275(51):40425\u201340433. https:\/\/doi.org\/10.1074\/jbc.M006854200","journal-title":"J Biol Chem"},{"issue":"23","key":"4941_CR33","doi-asserted-by":"publisher","first-page":"13231","DOI":"10.1073\/pnas.221290398","volume":"98","author":"LC Roisman","year":"2001","unstructured":"Roisman LC, Piehler J, Trosset JY, Scheraga HA, Schreiber G (2001) Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking. Proc Natl Acad Sci USA 98(23):13231\u201313236. https:\/\/doi.org\/10.1073\/pnas.221290398","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"4941_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0969-2126(03)00120-5","volume":"11","author":"JH Chill","year":"2003","unstructured":"Chill JH, Quadt SR, Levy R, Schreiber G, Anglister J (2003) The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding. Structure 11(7):791\u2013802. https:\/\/doi.org\/10.1016\/s0969-2126(03)00120-5","journal-title":"Structure"},{"issue":"8","key":"4941_CR35","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1021\/acs.bioconjchem.5b00275","volume":"26","author":"JZ Hui","year":"2015","unstructured":"Hui JZ, Tamsen S, Song Y, Tsourkas A (2015) LASIC: Light Activated Site-Specific Conjugation of Native IgGs. Bioconjug Chem 26(8):1456\u20131460. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00275","journal-title":"Bioconjug Chem"},{"key":"4941_CR36","unstructured":"Ren H, Lonning SM, Pederson NE, Rikova K, Tkachev A, Gu T (2018) Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof. WO2018112334A1, June 21, 2018"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04941-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04941-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04941-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:28:01Z","timestamp":1786933681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04941-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4941"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04941-6","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Ethics and consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving animal care, handling, and treatment complied with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of Suzhou Charles River Accelerator and Development Lab.","order":3,"name":"Ethics","label":"Animal research statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"92"}}